Background: Patient preference as well as concerns and difficulties with intravenous access and pharmaco-economic issues have driven the development of oral vinorelbine.
Background
Vinorelbine is a semi-synthetic vinca-alkaloid which has demonstrated broad clinical antitumour activity in a weekly intravenous (i.v.) schedule. Intravenous vinorelbine has been established as one of the most active agents in the treatment of non-small-cell lung cancer (NSCLC) [1] [2] [3] and advanced breast cancer (ABC) [4] . The development of oral chemotherapy may allow improvement of patient comfort and reduction of the constraints and overall cost of the treatment [5, 6] . A soft gelatin capsule was formulated and shown to be stable for at least 24 months. In a phase I dose-finding study in patients with ABC, the maximum tolerated dose was 100 mg/m 2 on a weekly schedule, and the recommended dose for further clinical investigations was 80 mg/m 2 [7] , Dose-limiting toxicities included neutropenia, nausea/vomiting and constipation. Preliminary evidence of activity was obtained in first and second-line treatment for ABC. An absolute bioavailability study compared an i.v. infusion of vinorelbine 25 mg/m 2 with an oral administration of 80 mg/m 2 [8] . The bioavailability of the oral form was 43% ± 14. Based on the linearity of vinorelbine pharmacokinetics whatever the route of administration [9] [10] [11] , it was established that the oral dose of 80 mg/m 2 corresponded to an i.v. dose of 30 mg/m 2 and the oral dose of 60 mg/m 2 to an i.v. dose of 25 mg/m 2 . Interestingly, the pharmacokinetic behaviour of capsules was compared in fed and fasting conditions and was found to be similar [10] . Phase II studies were conducted in NSCLC and ABC to assess the efficacy of oral vinorelbine as a single agent. As recommended in the phase I dose-finding study, we initially studied the toxicity profile of a weekly dose of 80 mg/m 2 . Due to safety concerns, the study regimen had to be modified, and the starting dose of oral vinorelbine was reduced to 60 mg/m 2 . We will hereby report the safety profiles of oral vinorelbine in these two consecutive steps of the clinical investigation.
Patients and methods
We report here the safety data from four phase II studies involving two different regimens of oral vinorelbin. each of which was evaluated in first line NSCLC and in ABC.
First step' Oral vinorelbine SO mg/in' weekly

Eligibility criteria
Patients were eligible if their ages were between 18 and 75 years, their performance status (PS) was less or equal to 2 and their haematological, hepatic and renal functions were normal. Both studies were approved by a local ethics committee. Patients were fully informed and gave written consent.
Treatment and follow-up
The breast cancer study was designed as a phase II In NSCLC. the study consisted in a randomised phase 11 trial comparing the new schedule of oral vinorelbine to i.v. vinorelbine 30 mg/m 2 /week with a two (oral) to I (i.v.) ratio Patients received oral vinorelbine 80 mg/m 2 weekly on an outpatient basis, in the presence of the physician. Dose delay by one or two weeks was recommended in case of grade > 2 haematotoxicity, grade > 3 neurotoxicity or grade > 3 liver function test abnormalities. A three-week or more delay resulted in treatment discontinuation. In NSCLC only, a dose reduction to 60 mg/m 2 was mandated for patients who experienced any grade 4 haematotoxicity or two consecutive dose delays due to haematotoxicity.
Evaluation of toxicity parameters
Toxicity was assessed by using NCI common toxicity criteria. Dose intensity (Dl) was calculated as the ratio between the cumulative administered dose and the overall duration of treatment 
Eligibility criteria
Because of some co-morbidities observed in the patients having experienced severe toxicity in the first step (see 'Results' section below), some eligibility criteria were modified in this second step: PS of patients with NSCLC was restricted to 0 and I, patients with active infection and/or requiring long-term oxygenotherapy were ineligible. Both studies were approved by a local ethics committee. Patients were fully informed and gave written consent.
Treatment and follow-up
The breast cancer study was designed as a phase II. In NSCLC. the study consisted in a randomised phase II trial comparing the new schedule of oral vinorelbine to i.v. vinorelbine 30 mg/m 2 /week with a 2 (oral) to 1 (i.v.) ratio. In this second step, schedule of oral vinorelbine was devised in order to adjust the dose to the haematological tolerance of an individual patient: a dose of 60 mg/m 2 /week was given for the first three administrations and subsequently increased to 80 mg/ m 2 /week in the absence of grade 4 neutropenia.The recommendations for dose delay by one or two weeks remained unchanged. Dose reduction from 80 to 60 mg/m 2 was mandated in case of grade 4 neutropenia or more than one episode of grade 3 neutropenia. Dose reescalation was possible after three courses given at reduced dose in the absence of severe haematotoxicity.
Evaluation of toxicity parameters
Toxicity and Dl were assessed as described in the first step. The phase II trial in ABC with the second regimen is still on-going. (55) 15 (18) 31 (37) 14 (17) Abbreviations: NSCLC -non-small-cell lung cancer; ABC -advanced breast cancer: PS -performance status; CT -chemotherapy. (77) 5 (6) 1 (1) 13 (16) 11 (14) 9 (11) No. of administrations (%) n = 708 219 (31) 39 (6) 19 (3) 176 (25) 30 (4) 44 (6) 366 ( 
Results
First step: Oral vinorelbine 80 mg/m 2 weekly
Patient characteristics
A total of 82 patients were recruited in the two first phase II studies from March 1996 to June 1997. Fortyseven chemotherapy-naive patients with stage IIIB-IV NSCLC and 35 first-line patients with ABC were enrolled. The main characteristics of the two groups of patients (with NSCLC and ABC, respectively) are shown in Table 1 . The median age of the overall population was 66.5 years and 72% had PS 1 or 2. The majority of patients with ABC had received prior radiotherapy and 14 of 35 (40%) had received prior adjuvant chemotherapy, whereas a few patients with NSCLC (4%) had received prior radiotherapy and none had received chemotherapy.
Treatment delivery
The median number of administrations tended to be higher in patients with ABC than in those with NSCLC (10 and 7, respectively). Fifty-four percent of the overall population required dose delay, of whom a small fraction (6%) experienced both dose delay and dose reduction. Overall, 16% of all administrations were delayed. The main reason for treatment modification was neutropenia. The median dose Dl was 72 mg/m 2 /week.
Toxicity
The main haematological toxicity of oral vinorelbine at 80 mg/m 2 /week was neutropenia. The incidences of haematological events were similar in NSCLC and ABC, and Table 2 shows the frequencies in the combined population. Grade 3-4 neutropenia affected 47% of patients and 10% of administrations. Twenty patients experienced either febrile neutropenia (14%) or neutropenic infection (11%). Most episodes of febrile neutropenia or neutropenic sepsis occurred following the first, second or third administration. Eight patients (10% of the overall population) died as a consequence of complicated neutropenia. Three patients had experienced one prior episode of uncomplicated grade 4 neutropenia before that preceding death, which resulted in treatment delay but not in dose reduction. Significant medical comorbidity at the time of study entry was identified in four of these patients, including active pulmonary infection, respiratory failure requiring oxygen therapy, severe cardiac insufficiency and liver ethylic steatosis. Non-haematological toxicities mainly consisted of mild to moderate nausea (61%) and vomiting (46%). No primary prophylaxis with antiemetics was mandated in any study. Secondary prophylaxis, usually with metoclopramide, was used in 47 patients (57%). Diarrhoea occurred in 57% of the patients, alopecia in 34%. The main neurotoxicity was neuroconstipation, which was reported in 27% of patients and was severe in 4%. Twelve per cent of the patients experienced stomatitis and oesophagitis, of mild to moderate intensity was seen in 9% of patients.
The excessive rate of toxic deaths led to the discontinuation of both phase II studies and in-depth review of safety data. The investigators' committee decided to further investigate oral vinorelbine in NSCLC and ABC patients by starting treatment at a reduced dose and by adding new exclusion criteria. Table 3 . The median age of the overall population was 63.5 years and 47% had PS 1 or 2. The majority of patients with ABC had received prior radiotherapy and 20 of 62 (14%) had received prior adjuvant chemotherapy. In NSCLC, six had received prior radiotherapy and none had received chemotherapy.
Treatment delivery
The median numbers of administrations were eight and nine in patients with NSCLC and ABC, respectively. Among the 138 patients treated, 14 patients were prematurely discontinued (12 for non drug-related reasons and two for drug-related toxicity) and four patients were still on treatment at the cut-off date for analysis. Out of the 120 patients who received at least four administrations, 115 (96%) underwent dose escalation from 60 to 80 (7) 40 (29) 20 (32) Abbreviations: NSCLC -non-small-cell lung cancer; ABC -advanced breast cancer; PS -performance status; CT -chemotherapy. mg/nr/week after the third administration. Among the five patients who remained at 60 mg/m 2 /week after three courses, the reason was grade 4 neutropenia in four and vomiting in one. A dose delay was required in 37% of patients, of whom 23% also had dose reduction. Median DI was 59.3 mg/m 2 /week (intended DI: 60 mg/nr/week) for the first three courses and 69.7 mg/m 2 /week (intended DI: 80 mg/m 2 /week) thereafter.
Toxicity
As in the previous step, neutropenia was the major toxicity. The percentage of patients experiencing neutropenia was 63% (62% in the NSCLC population and 64% in the ABC population). At this dosage, grade 3 or 4 neutropenia was reported in 42% of patients (Table 4) and 7% of administrations. Four patients (2.9%) experienced febrile neutropenia and fully recovered after hospitalisation and antibiotics. Five patients (3.6%) developed neutropenic infection which in one NSCLC patient resulted in septic shock and death. Grade 3 or 4 neutropenia resulted in dose reduction from 80 to 60 mg/nr/week in 26 patients. In ten patients, a dose reduction was performed by mistake. Gastrointestinal toxicities, mainly mild to moderate nausea, vomiting and diarrhoea were frequently reported (Table 5) . Their incidences appeared to be higher when the dose was increased from 60 to 80 mg/m 2 , remaining nevertheless Overall 138 (100) 110 (80) 87 (63) 68 (49) 12 (9) 39 (27) 13 (9) NSCLC 76 (55) 60 (79) 47 (62) 30 (39.5) 6 (8) 20 (63) 5(7) ABC 62 (45) 60 (80) 40 (64) 38 (61) 6 (9) 19 (31) 8 (13) Grade 3 or 4
No. of administrations n = 1430 12(8.7) 10 (7) 7 (5) 7 (4.7) 6(4.1) 2(1.4)
1 Worst grade by patient.
of mild to moderate intensity. Secondary prophylaxis with antiemetics, generally metoclopramide, was used with 79 patients (57%). Grade 3 or 4 events were uncommon (less than 9% of patients) and occasionally dose-limiting. One patient remained at 60 mg/m 2 because of vomiting. Vomiting usually occurred one to five hours after drug intake (median = five hours). Neurotoxicity was reported in 27% of patients and included neuroconstipation, mild paresthesias and/or loss of deep tendon reflexes, peripheral motor neuropathy (severe but completely reversible in 2% of patients), ataxia which occurred in one patient and was severe and persistent after drug discontinuation. Neuroconstipation was reported in 13 (9% of patients) and was only severe in two. A 73-year-old patient with NSCLC, experienced paralytic ileus associated with dehydration and electrolyte disorders, and died despite hospitalisation and supportive measures. The only toxic cardiac event was dysrhythmia, which occurred in two patients. Other drug-related toxicities included transient fever without infection (9% of patients), myalgia (11%), malaise/fatigue (18%) and alopecia of mild to moderate intensity (25%). Table 5 shows a comparable toxicity profile for both trials, except for diarrhoea, which appeared more common in ABC patients (61 vs. 39.5%), and neurological toxicity, which appeared more common in NSCLC patients (63 vs. 31%). In the i.v. vinorelbine arm of the randomised phase II study of NSCLC, 38 patients simultaneously received a median number of 8.5 courses at 30 mg/m 2 /week with a median DI of 23.8 mg/m 2 /week ( Table 6 ). The safety profiles of oral and i.v. vinorelbine were qualitatively similar. Nausea, vomiting and diarrhoea were more common following oral administration, whereas grade 4 neutropenia and neuroconstipation were more frequent after i.v. administration.
Discussion
The goal of this review was to evaluate the safety profile of two different regimens of oral vinorelbine in a pop- ulation of patients with NSCLC and ABC who were enrolled in four phase II studies. Oral vinorelbine was initially used at a dose of 80 mg/m 2 /week, as recommended in the phase I dose-finding study [7] , in two simultaneous phase II studies on NSCLC and ABC. Further evaluation of this regimen had to be stopped, due to the occurrence of toxic deaths secondary to febrile neutropenia or neutropenic sepsis. Most episodes were early events following one to three courses. Cobormid conditions which are usually considered high-risk factors for complicated neutropenia [11] were identified in half of the patients who developed lethal complication. Moreover, and despite the use of an adequate methodology, the estimation of the maximal tolerated dose in phase I studies may be inappropriate, due to the low number of patients. This may have led to overestimation of the chosen dose for the phase II trials.
A new regimen of oral vinorelbine with intrapatient dose escalation from 60 to 80 mg/m 2 /week after the first three administrations was investigated in two further clinical trials. This dose-adjustment approach was aimed at optimising the haematological tolerance of the patient while maintaining the efficacy reported for i.v. vinorelbine. A pharmacokinetic/pharmacodynamic relationship between heamatological toxicity and drug exposure was reported in the phase I studies of oral vinorelbine [12] . It was therefore reasonable to assume that an intrapatient dose escalation would allow an early detection of patients at risk of developing severe haematoxicity. Indeed, the incidence of grade 3 and 4 neutropenia was dramatically reduced following the first three courses. The incidence of febrile neutropenia and neutropenic infection was low throughout the treatment period and similar to that observed with i.v. vinorelbine [3, 4, [13] [14] [15] [16] . Gastro-intestinal toxicity was common but never severe, and since vomiting was in all cases delayed by more than five hours, it was unlikely to impact on drug absorption, which is completed within the first hours. Diarrhoea was observed in 49% of the patients and was significantly more frequent in ABC patients. Neuroconstipation was a rare adverse event in both types of tumours, but overall neurological effects were more pronounced in NSCLC patients. Such differences are difficult to interpret and, in our opinion, cannot be explained by the fact that 32% of ABC patients had received prior chemotherapy while NSCLC patients were chemotherapy-naive.
Oral formulations of anticancer drugs (i.e. etoposide, cyclophosphamide, methotrexate, idarubicin) have been available for many years. Their use has been limited by variability in absorption, unpredictable and incomplete bioavailability and risk of patient non-compliance [6] . Recently, interest in oral cancer chemotherapy has been stimulated by increased attention to patient convenience and preference, and to pharmacoeconomic issues. Many oral cytotoxic agents, such as oral fluoropyrimidines, platinum derivatives, camptothecins and vinorelbine are now being developed. Our experience shows that the decision to treat fragile patients with chemotherapy, irrespective of the route of administration, must then be carefully weighted. In the present study, intrapatient dose escalation based on haematological toxicity was used to achieve individual titration of the appropriate dosage of oral vinorelbine. This approach was also helpful in reducing variations in patient tolerance.
In conclusion, these phase II studies have allowed the development of an oral vinorelbine regimen with intrapatient dose escalation that has a manageable safety profile. Similar to i.v. chemotherapy, a close haematological monitoring is necessary in order to adjust the dose to the haematological tolerance of the patient. The safety profile of this regimen was shown to be qualitatively comparable to that of i.v. vinorelbine. Therefore, oral vinorelbine might be a good alternative to the i.v. form. However, a careful analysis of clinical data on its efficacy will be necessary and should be performed in the near future.
